AllAnalyst Report
logoArgusMay 11, 2021

Ligand Pharmaceuticals Incorporated: Waiting for more favorable entry point

Symbols
LGND
Sector(s)
Healthcare
Rating
Current Price
$70.57
Price Target
Earnings Estimate
Summary

Ligand Pharmaceuticals develops and acquires technologies used by pharmaceutical companies to discover and develop medicines. LGND has contributed its research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections, and low blood platelets, among other conditions. Its partners have programs in clinical development targeting seizure, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease. Ligand's business model focuses on drug discovery, early-stage drug development, and product reformulation. Its pharmaceutical partners focus on lat

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade